Research & Development

Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients

Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Pfizer commits $100m to support development of new antibiotics

Major drugmaker Pfizer has committed $100m to the new Antimicrobial Resistance (AMR) Action Fund, which will support the development of new antibiotics due to increasing antibiotic-resistant infections.

Oxygen Sensor InPro 6860iHD

Reliable Oxygen Measurements Continuous dissolved oxygen (DO) measurement is critical during fermentation and cell culture.

Vor Biopharma closes $110m Series B financing

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.

Goldfinch Bio raises $100m to develop therapies for kidney diseases

Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.

Sanofi, Translate Bio expand mRNA vaccine partnership in $2.3bn worth deal

Sanofi Pasteur has signed a fresh deal potentially worth up to $2.32bn with US-based Translate Bio to expand an existing partnership of developing vaccines for infectious diseases by using the latter's messenger RNA technology (mRNA technology).

Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic

Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, announced their collaboration with Renibus Therapuetics to develop a therapeutic for Covid-19.

Gilead Sciences to buy 49.9% stake in Pionyr Immunotherapeutics for $275m

US-based biopharmaceutical company Gilead Sciences has agreed to acquire 49.9% equity stake in Pionyr Immunotherapeutics for $275m.

Elemental Packaging

After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.